Moodmap

Moodmap is a desktop application designed to quantify ADHD symptoms through computer vision and computer usage data, offering a free local-use tier and a paid clinical trial option. Unlike subjective self-report tools, it replicates elements of a QB test by analyzing webcam footage of attention and movement alongside keystroke, mouse, and app-switching patterns. The core value proposition is objective, continuous symptom tracking that can be correlated with medication intake, giving users a data-driven view of how their focus fluctuates throughout the day and in response to treatment.

Where Moodmap stands out is its integration of multiple data streams—video, speech, and usage metrics—into a single dashboard, all without a subscription fee for local use. This makes it accessible for adults with ADHD who want to move beyond vague self-assessments and see concrete patterns in their attention. The medication monitoring feature is particularly practical: by logging dose times and reviewing correlated symptom graphs, users can identify when their medication peaks and wanes, helping optimize timing with their workflow. For clinicians, the app could serve as a remote monitoring bridge, offering structured data between appointments. The paid tier, called the Clinical Trial Pod, is a distinct model where users generate income by contributing data to research studies, rather than paying for premium features—a novel approach that aligns user and researcher incentives.

However, there are limits to consider. Moodmap is a desktop-only application, which means it cannot track symptoms on mobile or during commutes, potentially missing key context. The reliance on computer vision in uncontrolled home environments introduces variability—lighting, camera angle, and background distractions can affect accuracy, and the app has not undergone extensive independent validation outside the company's own research. Users should also be aware that while it mimics a QB test, it is not a diagnostic tool and should not replace professional evaluation. The data collected, including video and usage logs, raises privacy considerations, though local processing mitigates some risk.

For the practical buyer or operator, Moodmap is best suited as a complementary tracking tool for those already managing ADHD, rather than a standalone solution. It fits into a workflow where a user runs it during focused work sessions, reviews trends weekly, and adjusts medication timing or environment based on insights. The free tier makes it low-risk to trial, but the real value emerges with consistent use over weeks. Those considering the clinical trial pod should evaluate the time commitment and data sharing terms. In a crowded digital health space, Moodmap carves a niche by turning a computer into a passive attention sensor, offering a rare blend of objective measurement and free access—but its utility ultimately depends on how well users integrate its data into their broader ADHD management strategy.